Meletios A. Dimopoulos, MD, on the Future of a Combination Therapy in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.
Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Transcription:
It was reassuring to see that there was less gastrointestinal toxicity as compared to the STORM trial where selinexor was given as a single agent at higher doses. This is important as far as gastrointestinal tolerability which was a major problem in the single agent STORM trial. Also, it was reassuring to see that there was less peripheral neuropathy.
This combination could be evaluated in earlier phases of the disease especially in activity in patients with high-risk cytogenetics. It could be combined with anti-CD38 monoclonal antibodies to provide the quadruple that would include patient treatments and regimens with different mechanisms of action.
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
August 27th 2024Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.
